2 completed, 1 active not recruiting. 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Completed 2, Active not recruiting 1 |
Follow Howard University: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence Beta3-Agonists, Adrenergic [Mirabegron/Vibegron], OnabotulinumtoxinA 100 UNT [Botox] - Urgency Urinary Incontinence | Phase 4 | Active not recruiting | Women and Infants Hospital of Rhode Island | 432 | 2023-06-06 | 2026-06-29 |
| Suvorexant and Sleep's Benefits to Therapeutic Exposure for Posttraumatic Stress Disorder suvorexant, placebo - Posttraumatic Stress Disorder | Phase 4 | Completed | Howard University | 27 | 2017-01-03 | 2023-06-02 |
| Suvorexant and Trauma Related Insomnia suvorexant, placebo - Insomnia, Posttraumatic Stress Disorder | Phase 4 | Completed | Howard University | 41 | 2016-05-01 | 2023-02-15 |
Stress Disorders, Post-Traumatic (2) · Sleep Initiation and Maintenance Disorders (1)
suvorexant (2) · Adrenergic Agents (1) · Botulinum Toxins, Type A (1) · N-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide (1) · mirabegron (1)
United States (3)
Ihori Kobayashi, Ph.D. (1) · Peter Jeppson, MD (1) · Thomas A Mellman, M.D. (1) · Vivian Sung, MD, MPH (1)
K01MH110647 (1)